IDH1 and central nervous system cancer: The phase III “Investigating Non-enhancing Diffuse IDH-mutant Glioma Outcomes” (INDIGO) trial showed brain-penetrant IDH1/2 inhibition with vorasidenib prolonging progression-free survival in residual/recurrent IDH-mutant low-grade gliomas [13].